Pennington KL, DeAngelis MM (2016) Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis 3:34

Article  Google Scholar 

Yang S, Zhao J, Sun X (2016) Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther 10:1857–1867

CAS  PubMed  PubMed Central  Google Scholar 

Lux A, Llacer H, Heussen FMA, Joussen AM (2007) Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 91:1318–1322

Article  PubMed  PubMed Central  Google Scholar 

Amoaku WM et al (2015) Defining response to anti-VEGF therapies in neovascular AMD. Eye 29:721–731

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu W et al (2021) Adipose tissue-derived stem cells in plastic and reconstructive surgery: a bibliometric Study. Aesthetic Plast Surg 45:679–689

Article  PubMed  Google Scholar 

van Eck NJ, Waltman L (2010) Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 84:523–538

Article  PubMed  Google Scholar 

Keenan TDL, Cukras CA, Chew EY (2021) Age-related macular degeneration: epidemiology and clinical aspects. Adv Exp Med Biol 1256:1–31

Article  CAS  PubMed  Google Scholar 

Brown DM et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444

Article  CAS  PubMed  Google Scholar 

Heier JS et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548

Article  PubMed  Google Scholar 

Holekamp NM et al (2022) Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology 129:295–307

Article  PubMed  Google Scholar 

Koh GY, Augustin HG, Campochiaro PA (2022) Viewpoints: dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye. Trends Mol Med 28:347–349

Article  CAS  PubMed  Google Scholar 

Engelbert M, Zweifel SA, Freund KB (2010) Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified ‘treat and extend’ dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina 30:1368–1375

Article  PubMed  Google Scholar 

Engelbert M, Zweifel SA, Freund KB (2009) ‘Treat and extend’ dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina 29:1424–1431

Article  PubMed  Google Scholar 

Gillies MC et al (2003) A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 121:667–673

Article  CAS  PubMed  Google Scholar 

Lee J, Freeman WR, Azen SP, Chung EJ, Koh HJ (2007) Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: one-year results. Retina 27:1205–1213

Article  PubMed  Google Scholar 

Kaiser PK, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2006) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol 244:1132–1142

Article  CAS  PubMed  Google Scholar 

Azab M et al (2004) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: treatment of age-related macular degeneration with photodynamic therapy and verteporfin in photodynamic therapy study report no. 4. Retina 24:1–12

Article  PubMed  Google Scholar 

Schmidt-Erfurth U et al (2003) Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44:4473–4480

Article  PubMed  Google Scholar 

Rofagha S et al (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120:2292–2299

Article  PubMed  Google Scholar 

Tsujinaka H et al (2020) Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles. Nat Commun 11:694

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heier JS et al (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399:729–740

Article  CAS  PubMed  Google Scholar